newsfilter
← Latest News
Business Wire·

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

– Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients – Results of